{
    "guideline_identifier": "PIIS2059702924018921.txt",
    "cancer_focus": {
        "primary_cancer": "Sinonasal Malignancies",
        "related_syndrome_or_condition": ""
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Localized/Locoregional: Resectable",
            "risk_group": "High-risk (pT3/T4, positive margins, perineural invasion, lymph node involvement, high-grade histology)",
            "treatment_plans": [
                {
                    "clinical_context": "Resectable tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Endoscopic surgery (TES) for nasoethmoidal tumors; external approaches for maxillary sinus. Goal: Clear margins with intraoperative frozen sections. Followed by adjuvant radiotherapy.",
                    "treatment_line": "Primary",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level III, A"
                },
                {
                    "clinical_context": "High-risk resectable tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Adjuvant radiotherapy (IMRT standard). Proton/carbon-ion therapy for complex anatomy/radioresistant histologies.",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV, A"
                }
            ]
        },
        {
            "staging_criteria": "Localized/Locoregional: Resectable",
            "risk_group": "Low-risk (low-grade pT1 with negative margins)",
            "treatment_plans": [
                {
                    "clinical_context": "Low-risk tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Surgery without adjuvant radiotherapy",
                    "treatment_line": "Primary",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV, E"
                }
            ]
        },
        {
            "staging_criteria": "Localized/Locoregional: Unresectable",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Unresectable tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Definitive intensity-modulated radiotherapy (IMRT). Proton/carbon-ion therapy considered for complex anatomy.",
                    "treatment_line": "Definitive",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level IV, A"
                },
                {
                    "clinical_context": "High-grade unresectable tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Platinum-based chemoradiotherapy",
                    "treatment_line": "Definitive",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Localized/Locoregional: High-grade tumors",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "High-grade/poorly differentiated tumors (SNUC, SNEC, SCNEC, Hyams III/IV ONB)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Neoadjuvant chemotherapy: TPF (SCC/SNUC), PFL (ITAC), EI/IA (SNEC/SCNEC). Response-adapted therapy: Definitive CRT if response; surgery/CRT if no response.",
                    "treatment_line": "Neoadjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level III, A"
                }
            ]
        },
        {
            "staging_criteria": "Recurrent: Local/Regional",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Operable recurrence",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Salvage surgery ± reirradiation",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Inoperable recurrence",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Reirradiation (IMRT/proton therapy)",
                    "treatment_line": "Salvage",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Recurrent: Metastatic/Unresectable",
            "risk_group": "",
            "treatment_plans": [
                {
                    "clinical_context": "Metastatic/unresectable recurrence",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Palliative chemotherapy: cisplatin/5-FU ± taxanes/cetuximab; etoposide for neuroendocrine carcinomas. Local RT for symptomatic sites.",
                    "treatment_line": "Palliative",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Actionable biomarker-positive tumors",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "ESCAT-guided targeted therapy",
                    "treatment_line": "Palliative",
                    "biomarker_requirements": [
                        {
                            "name": "NTRK fusions",
                            "status": "Present",
                            "testing_guidance": "Tumor-agnostic testing by molecular profiling"
                        },
                        {
                            "name": "MSI-H",
                            "status": "Present",
                            "testing_guidance": "Tumor-agnostic testing by molecular profiling"
                        }
                    ],
                    "esmo_evidence_level": "Level IV, C"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Essential for histopathological classification (e.g., HPV for non-keratinizing SCC, NUT for carcinoma diagnosis), prognostication (IDH2 mutations predict less aggressive behavior), and guiding targeted therapy (ESCAT tiers)."
    }
}